Arcturus Therapeutics Holdings  logo
Arcturus Therapeutics Holdings ARCT
$ 8.35 1.46%

Quarterly report 2025-Q3
added 11-12-2025

report update icon

Arcturus Therapeutics Holdings Financial Statements 2011-2026 | ARCT

Annual Financial Statements Arcturus Therapeutics Holdings

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

432 M 968 M 962 M 688 M 1.47 B 125 M 50.3 M 24.7 M 28.7 M 111 M 84.4 M 223 M 20.7 M -

Shares

27 M 26.6 M 26.4 M 26.3 M 20.3 M 12.1 M 10.1 M 3.09 M 3.94 M 3.09 M 1.95 M 1.45 M 1.59 M -

Historical Prices

16 36.4 36.4 26.1 72.5 10.3 5 7.76 7.35 35.8 43.2 153 - -

Net Income

-80.9 M -29.7 M 9.35 M -204 M -72.1 M -26 M -21.8 M -10.9 M -24.6 M -19.4 M -32.8 M -10.5 M -1.58 M -3.93 M

Revenue

152 M 167 M 206 M 12.4 M 9.54 M 20.8 M 15.8 M 13 M - - - - - -

Gross Profit

- - - - 9.54 M - - - - - - - - -

Operating Income

-95.7 M -78.2 M 12.2 M -203 M -71.5 M -25.5 M -21.8 M - - - - - - -

Interest Expense

15.2 M 16.6 M -420 K -1.92 M -361 K -446 K 328 K - - - - - - -

EBITDA

-92.1 M -75.2 M 13.7 M -202 M -70.6 M -24.8 M -21.2 M -10.1 M -25.1 M -19.6 M -33 M -10.3 M -1.49 M -3.88 M

Operating Expenses

248 M 245 M 194 M 215 M 81.1 M 46.3 M 37.6 M 23.5 M 25.2 M 19.7 M 33.1 M - - -

General and Administrative Expenses

52.8 M 52.9 M 46.1 M 41.5 M 23.2 M 12.7 M 20.6 M 7.57 M 5.36 M 4.99 M 5.84 M 3.22 M 683 K 2.08 M

All numbers in USD currency

Quarterly Income Statement Arcturus Therapeutics Holdings

2025-Q3 2025-Q2 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

27.2 M 27.1 M 27.1 M 27.1 M 27 M 26.9 M 26.8 M 26.6 M 26.6 M 26.6 M 26.6 M 26.5 K 26.4 K 26.4 K 26.4 M 26.3 M 26.3 M 26.2 M 24.9 M 22.9 M 18.8 M 14.5 M 14.5 M 13.2 M 10.4 M 10.1 M 10.7 M 10.1 M 10.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-13.4 M -9.18 M - -6.9 M -17.2 M -26.8 M - -16.2 M -52.6 M 50.8 M - -35.3 M -21.6 M -51.2 M -38.7 M -54.1 M -54.6 M -56.3 M -31.1 M -21 M -10.3 M -9.78 M -11 M -7.43 M -685 K -6.88 M - -4.25 M -9.95 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

17.2 M 28.3 M - 41.7 M 49.9 M 38 M - 45.1 M 10.5 M 80.3 M - 13.4 M 27.1 M 5.24 M 5.79 M 2.44 M 2 M 2.13 M 2.24 M 2.33 M 2.32 M 2.65 M 2.97 M 3.32 M 10.2 M 4.35 M - 3.42 M 2.39 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-16.5 M -11.6 M - -10.7 M -21.1 M -30.4 M - -19.3 M -55.4 M 14.8 M - -36.8 M -22.1 M -50.4 M -37.6 M -53.8 M -53.7 M -57.7 M -31.1 M -20.9 M -10 M -9.46 M -10.8 M -7.62 M -572 K -6.51 M - -4.36 M -10.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

3.23 M 2.57 M - 3.82 M 4.15 M 4.02 M - 3.98 M 3.25 M 2.48 M - -321 K -560 K -564 K - -519 K -520 K -358 K - -66 K -121 K -152 K - -120 K -113 K -88 K - 150 K 169 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-15.7 M -10.8 M - -9.84 M -20.2 M -29.5 M - -18.5 M -54.7 M 15.3 M - -36.4 M -21.7 M -50.2 M -37.6 M -53.5 M -53.4 M -57.4 M -31.1 M -20.7 M -9.84 M -9.28 M -10.8 M -7.42 M -372 K -6.34 M - -4.16 M -9.97 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

33.7 M 39.9 M - 52.4 M 71 M 68.4 M - 64.5 M 65.9 M 65.5 M - 50.2 M 49.2 M 55.6 M - 56.3 M 55.7 M 59.8 M - 23.3 M 12.4 M 12.1 M - 10.9 M 10.7 M 10.9 M - 7.78 M 12.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

10.4 M 10.3 M - 13.3 M 12.3 M 14.9 M - 13.4 M 13.2 M 13.8 M - 12.5 M 11 M 10.7 M 10.8 M 10.9 M 10 M 9.74 M 9.03 M 5.57 M 4.42 M 4.19 M 1.79 M 3.88 M 3.46 M 3.53 M - 3.81 M 8.23 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Arcturus Therapeutics Holdings ARCT
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Arcturus Therapeutics Holdings plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alector Alector
ALEC
$ 2.08 -14.4 % $ 214 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Altimmune Altimmune
ALT
$ 4.2 -2.67 % $ 298 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.24 -3.44 % $ 2.55 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.8 1.87 % $ 4.36 M chinaChina
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.88 -3.72 % $ 3.18 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 7.2 -1.64 % $ 1.99 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.1 2.37 % $ 356 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Ardelyx Ardelyx
ARDX
$ 6.37 -2.75 % $ 1.54 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
argenx SE argenx SE
ARGX
$ 756.71 -1.33 % $ 25 B niderlandNiderland
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 10.91 1.58 % $ 394 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 25.33 -6.1 % $ 3.22 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Artelo Biosciences Artelo Biosciences
ARTL
$ 1.15 -3.36 % $ 2.32 M usaUSA
Arvinas Arvinas
ARVN
$ 12.97 -2.3 % $ 920 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 61.74 -2.42 % $ 8.26 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 231.56 -0.83 % $ 5 B danmarkDanmark
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.39 -1.63 % $ 8.16 B australiaAustralia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.17 -0.85 % $ 35.2 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 4.39 -0.9 % $ 553 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 5.01 -7.47 % $ 37.5 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 14.14 -0.21 % $ 1.9 B canadaCanada
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.68 -1.75 % $ 429 M britainBritain
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 4.69 0.21 % $ 395 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 4.54 2.44 % $ 387 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 570.5 5.18 % $ 43.2 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 162.28 -0.98 % $ 8.07 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.56 -0.58 % $ 16.1 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA